USFDA actions a key risk for Indian pharma companies: ICRA
From 2008-2015, USFDA has issued around 50 warning letters on Indian companies; out of these, around 40% were converted into import alerts
- Trade brawls get world’s top central bankers worried for growth
- India’s retaliatory tariff on US imports to come into effect from 4 August
- Monsoon may revive from next week: IMD forecast
- Impact of Metro on Hyderabad, Bengaluru traffic: What data shows
- Sushma Swaraj holds trade talks with Luxembourg PM Xavier Bettel
New Delhi: The increasing number of regulatory actions from the US Food and Drug Administration (USFDA) is emerging as a key risk for Indian pharmaceutical companies as it may delay product approvals and are likely to add to margin pressures, says a report by rating agency ICRA.
From 2008-2015, USFDA has issued around 50 warning letters on Indian companies. Out of these, around 40% were converted into import alerts. Sun Pharmaceutical Industries Ltd, Dr.Reddy’s Laboratories Ltd, Cadila Healthcare Ltd and IPCA Laboratories Ltd were the major companies that faced USFDA heat in 2015.
Issuance of warning letters and import alerts for India-based manufacturing facilities have increased significantly over the past couple of years following USFDA’s increasing focus on compliance of good manufacturing practices, the report says. It adds that one-third of warning letters issued between 2008 and 2013 have been resolved with majority of them belonging to large companies.
“In an environment where companies are going through pricing pressure owing to increased competitive intensity, these developments are likely to add to margin pressures. Nonetheless, we believe that the credit profile of affected entities is unlikely to be impacted in view of their strong balance sheets and liquidity,” the ICRA report says.
As a result of USFDA’s stringent follow up on manufacturing standards, pharmaceutical companies are now mandated to review their research and development and manufacturing procedures, implement comprehensive action plans and even conduct risk assessment of products that are already in the market. Based on the severity of the deviations, the FDA has also directed some companies to get third-party evaluation of their remediation processes.
The report also suggests that 50% of the warnings letters have been resolved within a period of 12-15 months. The escalation of warning letters to import alerts is also higher for small and mid-size companies.
Editor's Picks »
- Awareness of cyber threats to cryptocurrencies is very low in India: report
- JSW Steel plans bid for ArcelorMittal’s Galati plant in Romanian
- NSE algo trading case: Sebi to take action against involved entities
- RBI asks banks to upgrade ATMs for greater security
- Zuckerberg on cusp of topping Buffett with Facebook at $200
- Why Indian paint makers are shifting to water-based paints
- 2019 elections still some time away but defence stocks get the jitters
- Complan and Horlicks sale signals low energy in health drinks market
- With fall of the last dove, MPC minutes portend more than one RBI rate hike
- RITES IPO ticks the valuations box, but not the growth one